Sangamo Therapeutics Inc (SGMO) saw downtrend of -5.33% in the recent trading with $0.46 being its most recent. The current price level -85.63% lower than the highest price of $3.18 marked by the stock while trading over the past 52-weeks, whereas it is 11.14% higher than the lowest price of $0.41 the company dropped to over past 52-weeks. The latest news story on SGMO appeared in (Zacks) under the title “Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates”.
Looking into the simple moving average, Sangamo Therapeutics Inc (SGMO)’s stock stands at a SMA-50 of $0.5139 while that of 5-day is reading $0.5069.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and SGMO’s SMA-200 as of now is $1.0997.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.83 for the stock.
Sangamo Therapeutics Inc Earnings – What Happened With SGMO
Coming around sales and income figures on SGMO Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Sangamo Therapeutics Inc (SGMO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 200.00% for net revenue.
SGMO – Sangamo Therapeutics Inc Stock Earnings Estimates
The perspective of Sangamo Therapeutics Inc (NASDAQ:SGMO)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.04 for stock’s EPS in the current quarter. Sangamo Therapeutics Inc (SGMO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 200.00% for net revenue. Company’s EPS for the last quarter was 0.04.
Sangamo Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 272.80 million. SGMO does have institutional investors; and they hold 22.05% of the stock.
As on 2024-06-30, WASATCH ADVISORS LP was the top most holder in Sangamo Therapeutics Inc (NASDAQ:SGMO) with an ownership of 20.09 million shares of the company or 9.8509 of the stake worth $7.2 million. The filing also reveals ARMISTICE CAPITAL, LLC as the second largest holder in the company with a control over 6.894 of the outstanding shares. Its stake is worth $5.04 million for having 14.06 million shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 5.8341 of the outstanding shares. With this there are now 154.0 institutions which have possession in SGMO’s shares.
Key Metrics forSGMO
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Sangamo Therapeutics Inc has a debt to equity ratio of 1.20.
